Jinwon Life Sciences announced on the 25th that its subsidiary VGXI, a CDMO (Contract Development and Manufacturing Organization) specializing in nucleic acid-based biopharmaceuticals, has signed a multi-year partnership agreement with National Resilience, Inc. (hereinafter Resilience), which focuses on bio-manufacturing of complex medicines centered on technology, to produce advanced biopharmaceuticals.
Under this partnership agreement, VGXI will supply plasmid DNA necessary for the advanced biopharmaceuticals produced by Resilience, and Resilience will gain access to VGXI’s state-of-the-art analytical product portfolio for cell banks, active pharmaceutical ingredients, and finished pharmaceuticals.
A company representative stated, “Based on VGXI’s rapid production capacity and extensive CDMO experience, Resilience is expected to significantly improve production efficiency and quality in the growing field of cell and gene therapies (CGT).”
Younggeun Park, CEO of Jinwon Life Sciences, said, “We are pleased to strategically collaborate with Resilience, an outstanding CDMO company in the next-generation biopharmaceutical field of cell and gene therapies (CGT), to expand patient access to innovative medicines. This partnership agreement strongly expresses our commitment to resolving bio-manufacturing raw material supply issues through building a quality-focused network between the two companies.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
